Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2022 23:19 ET | Source: Nkarta, Inc.

Nkarta Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today...
April 25, 2022 16:01 ET | Source: Nkarta, Inc.

Nkarta Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today...
April 25, 2022 07:00 ET | Source: Nkarta, Inc.

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60%...
April 22, 2022 16:10 ET | Source: Nkarta, Inc.

Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates

Call scheduled for Monday, April 25, 2022 8:00 a.m. ET Clinical trial investigators to participate SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a...
April 08, 2022 13:25 ET | Source: Nkarta, Inc.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
April 08, 2022 07:58 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
March 29, 2022 08:02 ET | Source: Nkarta, Inc.

Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors

Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc....
March 17, 2022 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 1H 2022 - NKX101, a CAR NK cell therapy candidate engineered with NKG2D receptor, in relapsed/refractory...
March 08, 2022 16:35 ET | Source: Nkarta, Inc.

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
February 10, 2022 08:02 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right